Table 1 Comparison of the characteristics of the patients who received tocilizumab versus those who did not
Variable | Tocilizumab (n = 151) | Control (n = 118) | P value |
|---|---|---|---|
Age | 53 (44–60) | 55 (47–64) | 0.007 |
Male sex | 107 (70.9) | 69 (58.5) | 0.034 |
Hypertension | 40 (26.5) | 53 (44.9) | 0.002 |
Diabetes | 78 (51.7) | 59 (50) | 0.788 |
Obesity | 14 (9.3) | 0 (0) | 0.001 |
Other comorbidities | 5 (3.3) | 13 (11) | 0.012 |
Number of comorbidities | 1 (0–1) | 1 (1–2) | 0.031 |
No comorbidities | 55 (36.4) | 28 (23.7) | 0.035 |
Categorya | Â | Â | 0.036 |
 E | 125 (82.8) | 108 (91.5) |  |
 F | 26 (17.2) | 10 (8.5) |  |
Oxygen saturation | 86 (82–92) | 91 (88–93) | 0.001 |
Respiratory rate | 34 (30–40) | 30 ((27–38) | 0.137 |
Serum creatinine | 1 (1–1.9) | 1.3 (1–1.7) | 0.002 |
Non-invasive ventilation | 56 (37.1) | 0 (0) | 0.001 |
Invasive ventilation | 22 (14.6) | 8 (6.8) | 0.044 |
Deaths | 79 (52.3) | 74 (62.7) | 0.088 |